These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34555262)

  • 1. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures.
    Yoshiji H; Ueno Y; Kurosaki M; Torimura T; Hatano E; Yatsuhashi H; Yamakado K
    Hepatol Res; 2021 Dec; 51(12):1181-1195. PubMed ID: 34555262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study.
    Ding JN; Feng TT; Sun W; Cai XY; Zhang Y; Zhao WF
    World J Gastrointest Surg; 2022 Nov; 14(11):1260-1271. PubMed ID: 36504518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
    Loffredo L; Violi F
    Dig Liver Dis; 2019 Jan; 51(1):24-27. PubMed ID: 29958825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Flisiak R; Antonov K; Drastich P; Jarcuska P; Maevskaya M; Makara M; Puljiz Ž; Štabuc B; Trifan A
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
    Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
    BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
    Saab S; Bernstein D; Hassanein T; Kugelmas M; Kwo P
    J Clin Gastroenterol; 2020 Jul; 54(6):503-511. PubMed ID: 32195771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.